Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs).
Klotz
Ulrich
U
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D065731:Cytochrome P-450 CYP2C19; D015536:Down-Regulation; D004334:Drug Administration Schedule; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D005787:Gene Frequency; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D009853:Omeprazole / Q000008:administration & dosage / Q000493:pharmacokinetics; D010641:Phenotype; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D016896:Treatment Outcome
D054328:Proton Pump Inhibitors; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D009853:Omeprazole